Pharmacy Services
Celecoxib (Celebrex) cardiovascular risk
December 21, 2004
One of 3 ongoing studies with celecoxib (Celebrex) showed an increased risk of cardiovascular events. This study evaluated celecoxib for the prevention of colon polyps and at a mean of 33 months of therapy, the 400 mg/day and 800 mg/day groups showed a 2.5 and 3.4 fold increase in cardiovascular fatal or non-fatal events compared to placebo. The other two studies have not shown an increase in cardiovascular event risk. All three studies have been suspended. The FDA recommends using the lowest dose possible of celecoxib.
Additional information is available at:
- Drug Information Page:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103420.htm - Pfizer Press Release:
http://www.pfizer.com/are/investors_releases/2004pr/mn_2004_1217.cfm - FDA Alert:
http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124654.pdf
Updated
December 21, 2004; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.
Social Media
Copyright © 2013 University of Utah Health Care